Business
Interim Report
Interim Report.
About this update from Shield Therapeutics Plc
[{"type":"text","content":"\n \nRNS Number : 2243R Shield Therapeutics PLC 20 September 2017 \n\n\n \nShield Therapeutics plc\n(\"Shield\" or the \"Company\" or the \"Group\")\nInterim Report for the Six Months Ended 30 June 2017\n \nLondon, UK, 20 September 2017. Shield Therapeutics plc (LSE:STX), a specialty pharmaceutical company focused on secondary care, today announces its unaudited interim results for the six months ended 30 June 2017.\n \nHighlights (including post period end)\nOperational \n· Continued focus on early Feraccru® commercialisation initiatives in our first European target markets:\no Commercial team reorganised with Country Managers now reporting directly to the CEO to deliver increased focus on sales traction and maximise resources\no More than 20 specialist staff driving product recognition and sales ramp in Germany and the UK\no Application submitted to the EMA to extend the label for Feraccru to all patients with IDA\n· Delivering on strategy to out-license Feraccru across non-core markets via agreement with AOP for Scandinavia and Ewopharma for Switzerland\n· Clinical progress across multiple trials:\no The AEGIS-CKD pivotal Phase 3 study has recruited 97% of the required subjects with Last Patient In expected imminently, resulting in primary top line data expected in early 2018 \no AEGIS-H2H study progressing as per previous guidance, with data expected in H1 2018\no Data from the paediatric pharmaco...